Payment overview · 2025
General Payments
$146.77
7 reported records · 6 companies
Healthcare provider profile · identity verified
Mohammed Hussain, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · CHICAGO, IL · NPI 1649339441
Verified facts
What the public records show
CMS Open Payments records show Mohammed Hussain, MD received $146.77 in general payments during 2025 across 7 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $38.82 | 26.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.65 | 18.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.96 | 16.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.13 | 15.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.67 | 14.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.54 | 9.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.77 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $26.65 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 415 | 111 |
| Losartan Potassium | Losartan Potassium | 365 | 92 |
| Furosemide | Furosemide | 360 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 81 |
| Metformin Hcl | Metformin Hcl | 317 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 67 |
| Potassium Chloride | Potassium Chloride | 253 | 50 |
| Lisinopril | Lisinopril | 217 | 46 |
| Simvastatin | Simvastatin | 171 | 37 |
| Alprazolam | Alprazolam | 163 | 42 |
| Jardiance | Empagliflozin | 163 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 34 |
| Gabapentin | Gabapentin | 149 | 25 |
| Tramadol Hcl | Tramadol Hcl | 137 | 24 |
| Eliquis | Apixaban | 134 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 30 |
| Omeprazole | Omeprazole | 100 | 23 |
| Allopurinol | Allopurinol | 99 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 94 | 17 |
| Linzess | Linaclotide | 93 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 13 |
| Divalproex Sodium | Divalproex Sodium | 84 | suppressed |
| Azithromycin | Azithromycin | 83 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 17 |
| Naproxen | Naproxen | 81 | 24 |
| Lorazepam | Lorazepam | 79 | 20 |
| Meloxicam | Meloxicam | 76 | 34 |
| Levetiracetam | Levetiracetam | 74 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 23 |
| Digoxin | Digoxin | 60 | 14 |
| Famotidine | Famotidine | 60 | 14 |
| Glipizide | Glipizide | 60 | 14 |
| Glimepiride | Glimepiride | 57 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 33 |
| Carvedilol | Carvedilol | 55 | 18 |
| Enalapril Maleate | Enalapril Maleate | 54 | 17 |
| Prednisone | Prednisone | 52 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Sucralfate | Sucralfate | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 11 |
| Metolazone | Metolazone | 49 | 12 |
| Carbamazepine | Carbamazepine | 48 | suppressed |
| Clozapine | Clozapine | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 48 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 12 |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 46 | suppressed |
| Amoxicillin | Amoxicillin | 45 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 38 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Lactulose | Lactulose | 42 | suppressed |
| Risperidone | Risperidone | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 34 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Atenolol | Atenolol | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Zonisamide | Zonisamide | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Otezla | Apremilast | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 12 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Budesonide | Budesonide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.77 · 7 records | E.R. Squibb & Sons, L.L.C. | CAMZYOS, Cologuard Collection Kit, ELIQUIS, JARDIANCE, JAYPIRCA, NURTEC ODT, VERZENIO, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error